Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
Public ClinicalTrials.gov record NCT07504588. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Trial of Sacituzumab Govitecan-HZIY (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.
Study identification
- NCT ID
- NCT07504588
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 87 participants
Conditions and interventions
Conditions
- Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma
- Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma
- Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma
- Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma
- Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
- Anti-VEGF Monoclonal Antibody Biological
- Bevacizumab Biological
- Biospecimen Collection Procedure
- Carboplatin Drug
- Computed Tomography Procedure
- Echocardiography Test Procedure
- Gemcitabine Drug
- Magnetic Resonance Imaging Procedure
- Multigated Acquisition Scan Procedure
- Pegylated Liposomal Doxorubicin Hydrochloride Drug
- Sacituzumab Govitecan Biological
Biological · Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 24, 2026 (Actual)
- Primary completion
- Apr 12, 2029 (Estimated)
- Completion
- Apr 12, 2029 (Estimated)
- Last update posted
- Nov 5, 2026
2026 – 2029
United States locations
- U.S. sites
- 22
- U.S. states
- 8
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group - Fayetteville | Fayetteville | Arkansas | 72703 | Recruiting |
| Highlands Oncology Group - Rogers | Rogers | Arkansas | 72758 | Recruiting |
| Highlands Oncology Group | Springdale | Arkansas | 72762 | Recruiting |
| Kootenai Health - Coeur d'Alene | Coeur d'Alene | Idaho | 83814 | Recruiting |
| Kootenai Clinic Cancer Services - Post Falls | Post Falls | Idaho | 83854 | Recruiting |
| Kootenai Clinic Cancer Services - Sandpoint | Sandpoint | Idaho | 83864 | Recruiting |
| Carle at The Riverfront | Danville | Illinois | 61832 | Recruiting |
| Carle Physician Group-Effingham | Effingham | Illinois | 62401 | Recruiting |
| Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois | 61938 | Recruiting |
| Carle BroMenn Medical Center | Normal | Illinois | 61761 | Recruiting |
| Carle Cancer Institute Normal | Normal | Illinois | 61761 | Recruiting |
| Carle Cancer Center | Urbana | Illinois | 61801 | Recruiting |
| Mercy Hospital | Cedar Rapids | Iowa | 52403 | Recruiting |
| Oncology Associates at Mercy Medical Center | Cedar Rapids | Iowa | 52403 | Recruiting |
| Mercy Hospital Springfield | Springfield | Missouri | 65804 | Recruiting |
| Community Hospital of Anaconda | Anaconda | Montana | 59711 | Recruiting |
| Billings Clinic Cancer Center | Billings | Montana | 59101 | Recruiting |
| Benefis Sletten Cancer Institute | Great Falls | Montana | 59405 | Recruiting |
| Logan Health Medical Center | Kalispell | Montana | 59901 | Recruiting |
| Community Medical Center | Missoula | Montana | 59804 | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | Recruiting |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07504588, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2026 · Synced Nov 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07504588 live on ClinicalTrials.gov.